Departamento de Estudo de Populações, ICBAS, Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Rua de Jorge Viterbo Ferreira, n° 228, 4050-313, Porto, Portugal.
Center for Health Technology and Services Research, CINTESIS, Rua Dr. Plácido da Costa, s/n, 4200-450, Porto, Portugal.
Aging Clin Exp Res. 2022 Oct;34(10):2295-2304. doi: 10.1007/s40520-022-02200-1. Epub 2022 Sep 2.
Current demographic changes translate into an increased frequency of cancer in older adults. Available data show that about 45-55% of the new cancer patients will need RT treatments, with an expected increase of 20-30% in the future. To provide the best cancer care it is mandatory to assess frailty, offer appropriate curative treatments to patients and personalise them for the frail. Based on published data, the median prevalence of frailty in older population is about 42%. Recently, the free radical theory of frailty has been proposed stating that oxidative damage is more prevalent in frail patients. In parallel, RT is one of the most frequent cancer treatments offered to older adults and is a source of external free radicals. RT dose constraints correlate with toxicity rates, so we open the question whether frailty should be considered when defining these constraints. Thus, for this paper, we will highlight the importance of frailty evaluation for RT treatment decisions and outcomes.
目前人口结构的变化导致老年人癌症发病率的增加。现有数据显示，约 45-55%的新癌症患者需要接受 RT 治疗，预计未来这一比例将增加 20-30%。为了提供最佳的癌症护理，必须评估虚弱状况，为患者提供适当的治疗，并根据虚弱状况进行个体化治疗。根据已发表的数据，老年人中虚弱的中位患病率约为 42%。最近，提出了虚弱的自由基理论，该理论指出，脆弱患者中氧化损伤更为普遍。与此同时，RT 是提供给老年人的最常见癌症治疗方法之一，也是外部自由基的来源。RT 剂量限制与毒性发生率相关，因此我们提出了这样一个问题，即在定义这些限制时是否应考虑虚弱状况。因此，在本文中，我们将强调虚弱评估对 RT 治疗决策和结果的重要性。
Zotero 插件